ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AGY Allergy Therapeutics Plc

5.25
0.00 (0.00%)
Last Updated: 08:00:07
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.25 5.00 5.50 5.25 5.00 5.25 101,606 08:00:07
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 59.59M -43.07M -0.0090 -5.83 250.24M
Allergy Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 5.25p. Over the last year, Allergy Therapeutics shares have traded in a share price range of 0.85p to 6.05p.

Allergy Therapeutics currently has 4,766,439,938 shares in issue. The market capitalisation of Allergy Therapeutics is £250.24 million. Allergy Therapeutics has a price to earnings ratio (PE ratio) of -5.83.

Allergy Therapeutics Share Discussion Threads

Showing 2051 to 2074 of 5075 messages
Chat Pages: Latest  83  82  81  80  79  78  77  76  75  74  73  72  Older
DateSubjectAuthorDiscuss
19/2/2014
13:47
Cube
May sure you take the dog!!!

jimmyloser
19/2/2014
13:38
Every time there is a large sell, we seem to go up, will you guys all sell your shares please..Lol

Joking guys, Hold tight, we are going to the Moon....:0))

cube boss
19/2/2014
13:20
My AGY shares are held with the Halifax, if you go online, just do a dummy sell/ dummy buy and keep going until you get the buy / sell limits..:0))

If it keeps going, I may stop for 2 weeks!

Hope to have a peek while i'm away, but wont post well, maybe I won't be able to resist if we reach 20p! this rate we may reach before I leave..:0))

cube boss
19/2/2014
13:07
Cube Boss, where did you get the limits details, thanks?

FG

PS Stay in Lanzarote for 14 days, and then the share price may be over 30p by the time you get back.

farmer george
19/2/2014
11:36
What is going on here?
jimmyloser
19/2/2014
10:33
I like the last part of the RNS where they say, after already saying in a previous RNS they had a 12% increase across all territories.

"We continue to increase our market share"! (Continue)

May our market share Continue to increase!!...:0))

Think the results are going to be the Best...

Out for the rest of the day...GLA

cube boss
19/2/2014
10:05
Drop the share price and INCREASE the sell limits, come on Mr MMs, you can do better than that!.
Can sell 160,000 now..:0))

cube boss
19/2/2014
09:33
Llobet says " We look forward to updating" not we will update

Look forward !!!! hmmmm.

dyor/impo

jimmyloser
19/2/2014
09:10
I live near Yorkshire! and could even bring Black Puddings!
jimmyloser
19/2/2014
08:47
Jimmy, you forgot Italy, Spain and all the South Americas, in fact the world should wake up!!...:0))

A long dog walk, and then i'm going to make him a nice cooked breakfast for a treat...:0))

cube boss
19/2/2014
08:42
Your getting carried away like me Jimmy,:0)

£1 by Christmas is on as far as i'm concerned, remember we where £1.47p in 2007 before the FDA put the dreaded clinical hold on, but now all should run sweet!.

And if Dr Piyush Patel is at the Head of things, then what could go wrong?

Nice one Mr Tim Higenbottam...:0)

cube boss
19/2/2014
08:34
Cube, at this rate and with Germany, USA, UK and Canada all in the offing could we see £13.50/£14.00?

Take deep controlled breath Jimmy lol

jimmyloser
19/2/2014
08:32
19 February 2014

19 February 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study

Allergy Therapeutics, the fully integrated specialty pharmaceutical company, announces that the Canadian Health Authority, Health Canada, has approved the Company's proposal to submit a full Clinical Trial Application (CTA) for a new clinical efficacy study (G304) for Pollinex Quattro Grass MATA MPL (0.5ml). Health Canada reviewed the proposal and all supporting data at a meeting with the Company on 18(th) February 2014.

The meeting builds on the successful discussions held with the FDA, which resulted in the lifting of the clinical hold on the Company's clinical studies using vaccines containing the adjuvant monophosphoryl lipid A (MPL) in August 2012. Health Canada similarly had a hold on CTAs involving MPL. These decisions enable the Company to plan the start of the G304 study, which will involve two clinical sites in the USA as well as one in Canada.

The study, involving over 600 patients, will use multiple Environmental Exposure Chambers (EECs), allowing for controlled allergen exposure, to study the response to treatment with the new Pollinex Quattro Grass MATA MPL (0.5ml) compared to Grass MATA (0.5 ml) and placebo.

Patients will be exposed to grass pollen in the EECs before treatment and then after treatment, with the ultra-short course of four subcutaneous injections. An evaluation of long term efficacy, 12 months post treatment, in patients enrolled for the G304 study will also be made in the EECs.

The safety and efficacy advantages of the addition of MPL to the MATA products, previously seen in Allergy Therapeutics' Pollinex QuattroRagweed MATA MPL (0.5 ml), will be further determined during the G304 study. The full results of the ragweed clinical trial were recently published in the January print edition of The Journal of Allergy and Clinical Immunology(1) (JACI) and summarised in the Company press release dated 27(th) January 2014.

Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented:

"I am pleased with the progress we have made with the regulatory authorities in the US and Canada. The planned Environmental Exposure Chamber study for grass has been designed to build on the success of the Ragweed study, published in The Journal of Allergy and Clinical Immunology in January this year. The recent positive developments in the US allergy regulatory environment further underscore our confidence that North America will emerge as a valuable market for registered allergy vaccines. We continue to explore our strategic options for the development and commercialisation of Pollinex Quattro in this territory."

"In Europe we continue to grow the market share of our allergy products and I look forward to reporting fully on our market developments in the forthcoming Interim announcement."

(1) Piyush Patel, MD, Tom Holdich, MBBS, Karl J. Fischer von Weikersthal-Drachenberg, MD, and Birgit Huber, PhD. J Allergy Clin Immunol. 2014 133(1):121-129.e2.

jimmyloser
19/2/2014
08:22
Ooooppps, change that, Up she goes..:0)

Can now only buy 25k @ 14p

Can sell 150k @ 13.65p

Yet again, they want you to sell......:0)))

Can't have mine, these sort of companies don't come around very often!

And we are BRITISH...:0))

cube boss
19/2/2014
08:19
Max buy is 50k @ 14p
can sell 100k @ 13.275

They have been encouraging sells for a month or 2 ..:0))

cube boss
19/2/2014
08:09
wow...cube what are the current online limits

Appears as if someone wants these desperately impo/dyor

jimmyloser
19/2/2014
07:56
Looks like we are going to be Marked up this AM..:0)

Onwards and up.:0)

cube boss
19/2/2014
07:49
All good news, those who jumped ship yesterday will find it hard to get in for less now, and in the future!.
As you say AuDigger, this will strengthen our position with a US tie up..:0))

Should be interesting today..GLA..:0)

The fact that there will be 2 clinical sites in the US as well as 1 in Canada, speaks volumes! should put us in the driving seat to be the first into the US..

What's your thoughts Jimmy?

cube boss
19/2/2014
07:44
I wouldn't say that. I am happy at this level until they have some solid news to say. Up to now it's still jam (conserve) to-morrow.

Can see people not wanting to miss out here - if they do deliver the big news, it's awesome just high this could go. I may not be able to take it !!!

Steady away for me. I am very encouraged by the interest in the share and attracting and securing TH was just brilliant.

impo/dyor

jimmyloser
19/2/2014
07:26
Good news! Although the elusive US partner tie-up has yet to happen, this makes it more likely to come to fruition sooner rather than later. EU also doing well. 21p by results day!
audigger
18/2/2014
18:05
The current underlying strength here is good to see.

Thanks for the buy limit updates Cube.

How much do you want for that dog?
lol

jimmyloser
18/2/2014
15:26
Possibly will see a buy later on again, can sell 125,000 @ 13p
Max buy is 50,000 @ 13.25

buy order in at around 13.125 again..

cube boss
18/2/2014
14:35
Looks like the shake worked, maybe filled another order!..:0)))
cube boss
18/2/2014
11:47
Fed up now, going dog walking,...Small trades either way will move the share price

Happy holding long term!, only going one way!...:0))

cube boss
Chat Pages: Latest  83  82  81  80  79  78  77  76  75  74  73  72  Older

Your Recent History

Delayed Upgrade Clock